RxDoctor Payments Data

Sara Bailey, APRN

Psychiatric/Mental Health · Dublin, OHNPI 1699381368

Payments from drug & device makers

$4,686in general payments, 2019–2025

Across 206 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$731
  • AbbVie$652
  • Teva Pharmaceuticals USA, Inc.$578
  • Neurocrine Biosciences, Inc.$534
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$527
  • Otsuka America Pharmaceutical, Inc.$428
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,53297%
  • Education$1543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,686 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$5,707
Medicare patients
17
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl33$48,877
CaplytaLumateperone Tosylate24$38,075
Lurasidone Hcl51$37,821
Abilify MaintenaAripiprazole12$34,702
RexultiBrexpiprazole19$28,879
TrintellixVortioxetine Hydrobromide19$12,581
Ziprasidone Hcl58$5,631
Quetiapine Fumarate ErQuetiapine Fumarate16$4,427
Aripiprazole48$1,856
Zolpidem Tartrate ErZolpidem Tartrate13$1,444
Buspirone Hcl98$1,203
Divalproex Sodium ErDivalproex Sodium11$1,112
Duloxetine Hcl72$998
Sertraline Hcl87$886
Quetiapine Fumarate66$883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$428$63,58131 claims
AbbVieVraylar$652$48,87733 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$527$38,07524 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$66$12,58119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →